» Articles » PMID: 28841084

Human Papillomavirus Vaccination and Pap Smear Uptake Among Young Women in the United States: Role of Provider and Patient

Overview
Date 2017 Aug 26
PMID 28841084
Citations 7
Authors
Affiliations
Soon will be listed here.
Abstract

Background: It has been reported that Pap smear use is higher among U.S. women who received the human papillomavirus (HPV) vaccine than unvaccinated women. This study assessed the role of provider and patient in the difference of Pap smear use by vaccination status.

Methods: We conducted a cross-sectional study of 5416 young women (21-30 years of age) with detailed information on Pap smear use and HPV vaccination status from the National Health Interview Survey (NHIS) 2013-2015. Vaccinated women received at least one dose of HPV vaccine. Main outcomes included Pap smear in the past year, provider's recommendation for Pap smear, and patient-initiated Pap smear.

Results: The prevalence of Pap smear in the past year was much higher among vaccinated women than unvaccinated women (67.5% vs. 52.8%, p < 0.001). Compared with unvaccinated women, vaccinated women were more likely to receive a provider's recommendation for Pap testing (60.8% vs. 50.8%, p < 0.001), to obtain Pap testing after receiving a provider's recommendation (75.1% vs. 67.9%, p = 0.004), and to initiate Pap testing themselves (57.7% vs. 38.2%, p < 0.001). However, among women who visited an obstetrician/gynecologist (OB/GYN) in the past year, the positive association between HPV vaccination and Pap smear recommendation and uptake vanished.

Conclusions: Unvaccinated women who have not visited an OB/GYN in the past year are less likely to receive a recommendation for Pap testing from their providers or to initiate Pap testing themselves without a provider's recommendation. They should be encouraged to visit an OB/GYN provider for cervical cancer screening.

Citing Articles

Vaccine Confidence and Coverage among Medical Students at a Federal University in Brazil.

Feijo R, Bertotto J, Pinto A, Leal M, de Souza V, Sakai V Vaccines (Basel). 2024; 12(9).

PMID: 39340025 PMC: 11435744. DOI: 10.3390/vaccines12090993.


Cervical Cancer Screening and Prevention Uptake in Females with Autism Spectrum Disorder.

Chen Y, Powers J, McDougle C, Zurcher N, Thom R J Autism Dev Disord. 2024; .

PMID: 39294385 DOI: 10.1007/s10803-024-06565-2.


HPV self-collection for cervical cancer screening among survivors of sexual trauma: a qualitative study.

Madding R, Currier J, Yanit K, Hedges M, Bruegl A BMC Womens Health. 2024; 24(1):509.

PMID: 39272185 PMC: 11395272. DOI: 10.1186/s12905-024-03301-x.


Assessment of US Preventive Services Task Force Guideline-Concordant Cervical Cancer Screening Rates and Reasons for Underscreening by Age, Race and Ethnicity, Sexual Orientation, Rurality, and Insurance, 2005 to 2019.

Suk R, Hong Y, Rajan S, Xie Z, Zhu Y, Spencer J JAMA Netw Open. 2022; 5(1):e2143582.

PMID: 35040970 PMC: 8767443. DOI: 10.1001/jamanetworkopen.2021.43582.


Disparity of Cervical Cancer Risk in Young Japanese Women: Bipolarized Status of HPV Vaccination and Cancer Screening.

Taniguchi M, Ueda Y, Yagi A, Miyoshi A, Tanaka Y, Minekawa R Vaccines (Basel). 2021; 9(3).

PMID: 33808630 PMC: 8003385. DOI: 10.3390/vaccines9030280.


References
1.
Joura E, Giuliano A, Iversen O, Bouchard C, Mao C, Mehlsen J . A 9-valent HPV vaccine against infection and intraepithelial neoplasia in women. N Engl J Med. 2015; 372(8):711-23. DOI: 10.1056/NEJMoa1405044. View

2.
Caplan L, McQueen D, Qualters J, Leff M, Garrett C, Calonge N . Validity of women's self-reports of cancer screening test utilization in a managed care population. Cancer Epidemiol Biomarkers Prev. 2003; 12(11 Pt 1):1182-7. View

3.
Luque J, Tyson D, Markossian T, Lee J, Turner R, Proctor S . Increasing cervical cancer screening in a Hispanic migrant farmworker community through faith-based clinical outreach. J Low Genit Tract Dis. 2011; 15(3):200-4. PMC: 3735442. DOI: 10.1097/LGT.0b013e318206004a. View

4.
de Sanjose S, Quint W, Alemany L, Geraets D, Klaustermeier J, Lloveras B . Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study. Lancet Oncol. 2010; 11(11):1048-56. DOI: 10.1016/S1470-2045(10)70230-8. View

5.
Guo F, Hirth J, Berenson A . Comparison of HPV prevalence between HPV-vaccinated and non-vaccinated young adult women (20-26 years). Hum Vaccin Immunother. 2015; 11(10):2337-44. PMC: 4635939. DOI: 10.1080/21645515.2015.1066948. View